Microbial bile salt hydrolases mediate the efficacy of faecal microbiota transplant in the treatment of recurrent Clostridioides difficile infection by Mullish, Benjamin H et al.
  1Mullish BH, et al. Gut 2019;0:1–10. doi:10.1136/gutjnl-2018-317842
Gut microbiota
Original article
Microbial bile salt hydrolases mediate the efficacy of 
faecal microbiota transplant in the treatment of 
recurrent Clostridioides difficile infection
Benjamin H Mullish,  1 Julie a K McDonald,  1 alexandros Pechlivanis,1 
Jessica r allegretti,2,3 Dina Kao,4 grace F Barker,1 Diya Kapila,1 elaine O Petrof,5 
Susan a Joyce,6,7 cormac g M gahan,6,8 izabela glegola-Madejska,9 
Horace r t Williams,1 elaine Holmes,1 thomas B clarke,9 Mark r thursz,1 
Julian r Marchesi1,10
To cite: Mullish BH, 
McDonald JaK, Pechlivanis a, 
et al. Gut epub ahead of 
print: [please include Day 
Month Year]. doi:10.1136/
gutjnl-2018-317842
 ► additional material is 
published online only. to view 
please visit the journal online 
(http:// dx. doi. org/ 10. 1136/ 
gutjnl- 2018- 317842).
For numbered affiliations see 
end of article.
Correspondence to
Professor Julian r Marchesi, 
Division of integrative Systems 
Medicine and Digestive Disease, 
Department of Surgery and 
cancer, Faculty of Medicine, 
imperial college london, 
london SW7 2aZ, UK;  
 j. marchesi@ imperial. ac. uk
received 31 October 2018
revised 26 December 2018
accepted 15 January 2019
© author(s) (or their 
employer(s)) 2019. re-use 
permitted under cc BY. 
Published by BMJ.
AbsTrACT
Objective Faecal microbiota transplant (FMt) 
effectively treats recurrent Clostridioides difficile infection 
(rcDi), but its mechanisms of action remain poorly 
defined. certain bile acids affect C. difficile germination 
or vegetative growth. We hypothesised that loss of 
gut microbiota-derived bile salt hydrolases (BSHs) 
predisposes to cDi by perturbing gut bile metabolism, 
and that BSH restitution is a key mediator of FMt’s 
efficacy in treating the condition.
Design Using stool collected from patients and 
donors pre-FMt/post-FMt for rcDi, we performed 
16S rrna gene sequencing, ultra performance liquid 
chromatography mass spectrometry (UPlc-MS) bile 
acid profiling, BSH activity measurement, and qPcr of 
bsh/baicD genes involved in bile metabolism. Human 
data were validated in C. difficile batch cultures and a 
c57Bl/6 mouse model of rcDi.
results From metataxonomics, pre-FMt stool 
demonstrated a reduced proportion of BSH-producing 
bacterial species compared with donors/post-FMt. 
Pre-FMt stool was enriched in taurocholic acid (tca, 
a potent C. difficile germinant); tca levels negatively 
correlated with key bacterial genera containing BSH-
producing organisms. Post-FMt samples demonstrated 
recovered BSH activity and bsh/baicD gene copy number 
compared with pretreatment (p<0.05). in batch cultures, 
supernatant from engineered bsh-expressing E. coli 
and naturally BSH-producing organisms (Bacteroides 
ovatus, Collinsella aerofaciens, Bacteroides vulgatus 
and Blautia obeum) reduced tca-mediated C. difficile 
germination relative to culture supernatant of wild-type 
(BSH-negative) E. coli. C. difficile total viable counts 
were ~70% reduced in an rcDi mouse model after 
administration of E. coli expressing highly active BSH 
relative to mice administered BSH-negative E. coli 
(p<0.05).
Conclusion restoration of gut BSH functionality 
contributes to the efficacy of FMt in treating rcDi.
InTrODuCTIOn
Clostridioides difficile (previously named Clos-
tridium difficile1) infection (CDI) is the major global 
cause of nosocomial GI infection, with incidence 
significance of this study
What is already known on this subject?
 ► Faecal microbiota transplant (FMT) effectively 
treats recurrent Clostridioides difficile infection 
(rCDI), but has drawbacks associated with its 
use. Furthermore, its mechanisms of action 
remain poorly defined.
 ► There is an association between rCDI 
and altered gut bile acid profiles, but the 
significance of this remains unclear.
What are the new findings?
 ► Patients successfully treated for rCDI by FMT 
showed a rapid and sustained enrichment in 
gut microbiota members which produce a bile-
metabolising enzyme, bile salt hydrolase (BSH).
 ► Relative abundance of gut BSH-producing 
organisms correlates negatively with stool 
levels of taurocholic acid (TCA), a potent trigger 
for C. difficile germination. TCA is hydrolysed 
by BSH to cholic acid; this is subsequently 
metabolised into deoxycholic acid, which 
potently inhibits the growth of C. difficile.
 ► In batch cultures, BSH-producing 
microorganisms completely reversed TCA-
mediated germination of C. difficile.
 ► BSH-producing microbes significantly reduced 
faecal counts of C. difficile after administration 
to an rCDI mouse model compared with 
administration of a BSH-negative microbes.
How might it impact on clinical practice in the 
foreseeable future?
 ► Restored gut BSH functionality plays a central 
role in the efficacy of FMT in treating CDI.
 ► Targeted restoration of this function within 
the gut (eg, BSH-producing microorganisms, 
purified BSH enzyme) represents a novel 
therapeutic approach to treating rCDI which 
avoids the limitations associated with FMT.
 ► BSH supplementation merits further evaluation 
for its potential role as a therapy for human 
patients with rCDI.
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rates increasing worldwide.2 3 One therapeutic strategy for 
recurrent CDI (rCDI) that has come to prominence is faecal 
microbiota transplant (FMT). FMT has been demonstrated to be 
a highly effective therapy for rCDI, with cure rates of >80% in 
randomised trials,4 and up to >90% in case series where it was 
administered colonoscopically.5 However, FMT is not without 
drawbacks, including its unpalatability, the theoretical risk of 
infection transmission and its regulatory complexity.6 
Understanding the mechanisms underlying the efficacy of 
FMT in treating CDI may allow formulation of novel, more 
targeted, anti-CDI therapeutics. In a pilot study, sterile faecal 
filtrate was shown to be an effective treatment for rCDI in five 
patients,7 consistent with bacterially derived proteins, gut metab-
olites, bacteriophages or other filtrate components mediating 
the efficacy of FMT in treating this condition, as opposed to 
intact microorganisms. While the possible contribution of such 
mediators to FMT are starting to be elucidated,8–10 they remain 
incompletely defined.
One particular area of interest concerns the interaction 
between the gut microbiota and host bile acid metabolism in 
rCDI. In vitro, certain bile acids differentially affect the ability 
of C. difficile to undergo germination and vegetative growth. 
In particular, the conjugated primary bile acid taurocholic acid 
(TCA) is a potent trigger of C. difficile germination (with glycine 
as co-germinant),11 while the secondary bile acid deoxycholic 
acid (DCA) markedly inhibits vegetative growth.11 12 The transi-
tion from conjugated primary bile acids to secondary bile acids in 
vivo principally involves two enzymatic steps, with both enzymes 
produced by microbes but not mammals (see online supplemen-
tary figure 1). The first step is undertaken by bile salt hydrolases 
(BSHs), which deconjugate the taurine and glycine groups via a 
hydrolysis reaction, and consequently reform the unconjugated 
primary bile acids cholate and chenodeoxycholate. BSHs are 
widely distributed throughout most major bacterial divisions 
and archaea species of the gut microbiota, and at least eight 
different bsh genes exist13 (see online supplementary figure 2). 
The second enzymatic step is 7-α-dehydroxylation, whereby 
unconjugated primary bile acids are converted to secondary bile 
acids, including deoxycholate and lithocholate.
At present, there are only limited data exploring the possible 
contribution of BSHs to CDI vulnerability,14 and none investi-
gating the effect of FMT on BSH functionality. Given the key 
contribution of BSH’s substrate, TCA, to the germination of C. 
difficile, this is a clear potential mechanistic explanation for the 
efficacy of FMT. As such, using a work flow including human 
samples, batch cultures and mouse models, we investigated the 
hypothesis that patients with rCDI are deficient in gut microbiota 
members which produce BSH, with the consequent enrichment 
in TCA (promoting C. difficile germination) and loss of DCA 
(permitting vegetative growth) contributing to ongoing disease. 
We further hypothesised that successful FMT recolonises the 
gut microbiota with BSH-producing organisms, contributes to 
the restoration of the normal bile acid milieu of the gut, and 
consequently removes key triggers for C. difficile germination 
and vegetative growth.
MATerIAls AnD MeTHODs
study participants and FMT protocols
For the main human data set, stool samples were collected 
from participants with rCDI (26 participants; samples 
collected pre- FMT and at 8–12 weeks post-FMT) and 
their FMT donors (17 participants). rCDI was diag-
nosed on a combination of clinical and laboratory criteria 
(see online supplementary methods 1.1). Patient character-
istics are described in online supplementary table 1; none of 
the included patients had IBD. For validation of initial find-
ings, stool samples were also analysed for patients with rCDI 
from a Canadian randomised controlled trial investigating 
capsulised versus colonoscopic FMT as rCDI treatment (18 
participants; samples collected pre-FMT and at 1, 4 and 12 
weeks post-FMT), together with donors (five participants).15 
FMT slurry was also collected from these donors.
Donor inclusion/exclusion criteria, screening and 
testing followed previously described recommendations.16 
FMT protocols used are detailed in online supplementary 
methods 1.1.
DnA extraction and 16s rrnA gene sequencing
DNA was extracted from 250 mg of stool using a previ-
ously described protocol.17 16S rRNA gene qPCR data were 
used to determine total bacterial biomass within each sample 
(see online supplementary methods 1.2). Sample libraries were 
prepared following Illumina’s 16S Metagenomic Sequencing 
Library Preparation Protocol18 with several modifications.17 
The V1-V2 regions of the 16S rRNA gene were amplified using 
previously reported primers.17 The methodology for metatax-
onomic analysis is described in online supplementary methods 
1.3. We also predicted the bile metabolising ability of microbial 
communities using a metagenomic inferential tool, Piphillin19 
(see online supplementary methods 1.4).
uPlC-Ms profiling of faecal bile acids
The protocol used for initial sample processing17 and for anal-
ysis20 was as previously described. Methodology for prepro-
cessing and analysis of ultra performance liquid chromatography 
mass spectrometry (UPLC-MS) bile acid data is described 
in online supplementary methods 1.5.1. Integration of metatax-
onomic and UPLC-MS bile profiling data is described in online 
supplementary methods 1.6
Abundance and activity of bile metabolising enzymes
qPCR was performed using extracted DNA to quantify gene 
abundance for (1) specified groups of bsh (using degenerate 
primer sets previously reported)17 and (2) baiCD (using previ-
ously described primers21) (see online supplementary methods 
1.7). The BSH activity assay was an adaptation of the conven-
tional precipitation-based assay,22–24 using a previously described 
technique.17
C. difficile germination batch cultures
These were performed via adaptation of a previously described 
protocol.11 C. difficile spore preparation and enumeration is 
described in online supplementary methods 1.8. A range of 
different bacterial species established to produce BSH from 
different BSH groups (and Clostridium scindens, as a known 
7-α-dehydroxylase-producer) were incubated in sBHI (brain 
heart infusion broth (Sigma-Aldrich), with 5 mg/mL yeast extract 
(Sigma-Aldrich), and 0.1% w/v L-cysteine (Sigma-Aldrich)), 
with or without 1% w/v TCA added (see online supplementary 
methods 1.7). This list also included wild-type E. coli MG1655 
(which does not contain bsh genes within its genome), along 
with two forms of E. coli MG1655 into which bsh genes had 
been cloned using pBKminiTn7GM2 under the control of the 
P44 promotor25 (see online supplementary methods 1.7). C. 
difficile spores from three different ribotypes (a non-toxigenic 
ribotype, 010 (strain DS1684), and two toxigenic ribotypes, 
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012 (strain CD630) and 027 (strain R20291)) were resuspended 
in supernatant in triplicate, and an OD600 reading taken on a 
microplate reader at time zero (adjusted to OD600 of ~0.1 with 
supernatant/sBHI mix), and again after overnight incubation. An 
increased OD600 reading after overnight incubation was inter-
preted as indicating that spores had undergone germination 
and had grown as vegetative cells.11 Additionally, UPLC-MS 
was performed on batch culture supernatants to establish bile 
acid profiles (see online supplementary methods 1.5.2), and 
BSH activity assays were performed on spent supernatant from 
selected batch cultures.
recurrent C. difficile mouse model
Wild-type C57BL/6 mice (8–10 weeks old; female) were 
purchased from Envigo (Huntingdon, UK) and acclimatised for 
1 week before use. Mice were housed five per cage in individu-
ally ventilated cages with autoclaved food (RM1, Special Diet 
Services, Essex, UK), bedding (Aspen chip two bedding, North-
eastern Products Corporation (NEPCO), Warrensburg, New 
York) and water (provided ad libitum). Mice were subjected to a 
12 hours light and 12 hours dark cycle at 20°C–22°C.
We adapted a previously published mouse model of rCDI/
FMT26 (figure 1A). Mice were initially given cefoperazone 
0.5 mg/mL (Melford, Ipswich, UK) in their drinking water for 
5 days (day −7 to day −2), followed by challenge with 103 C. 
difficile spores by oral gavage on day 0. Mice were then treated 
with vancomycin 0.4 mg/mL together with streptomycin 5 mg/
mL (both Melford, Ipswich, UK) in their drinking water for 3 
days (days 4–7), followed by autoclaved antibiotic-free water 
for the remainder of the experiment. On both days 9 and 10, 
mice were fed by oral gavage either with ~109 colony-forming 
units (CFUs) of wild-type E. coli (n=5) or E. coli BSHhigh (n=5) 
(see online supplementary methods 1.7). Serial faecal samples 
were collected and C. difficile total viable counts (TVCs) quanti-
fied until E. coli colonisation began to decline (see online supple-
mentary methods 1.9). Administered E. coli were quantified by 
plating on MacConkey agar plates supplemented with rifam-
picin 50 µg/mL (Melford, Ipswich, UK). Mice were not fasted 
before oral gavages and all interventions were performed during 
the light cycle.
statistical analysis
This is summarised in online supplementary methods 1.10.
resulTs
successful FMT for rCDI is associated with restoration of bsH-
producing gut microbial community members from all bsH 
groups
We used microbial sequencing to evaluate whether FMT for rCDI 
was associated within an increase in BSH-producing microbes 
within the faecal microbiota. Further analysis of metataxonomic 
Figure 1 Impact of BSH on a mouse model of rCDI. A mouse model of rCDI/FMT was used that was adapted from a previously described model.26 
(A) Protocol for mouse model (*: stool samples taken for C. difficile and/or E. coli counts); (B) Counts of administered E. coli on day 12; (C) Total 
vegetative counts of C. difficile on day 12. CFU counts as established from plate counts of serial dilutions of faecal supernatant (*, p<0.05, Mann-
Whitney U test). BSH, bile salt hydrolases; CFU, colony-forming unit; FMT, faecal microbiota transplant; rCDI, recurrent C. difficile infection. 
 o
n
 25 February 2019 by guest. Protected by copyright.
http://gut.bmj.com/
G
ut: first published as 10.1136/gutjnl-2018-317842 on 11 February 2019. Downloaded from 
4 Mullish BH, et al. Gut 2019;0:1–10. doi:10.1136/gutjnl-2018-317842
Gut microbiota
data is provided in online supplementary results, figures 3–5 and 
table 2.
Bacterial species enriched in the faecal microbiota of 
healthy donors compared with pre-FMT samples were char-
acterised by a range of BSH-producing organisms, including 
members of group 1 (Bacteroides ovatus, q=0.017; Bacte-
roides uniformis, q=0.007), group 2 (Bifidobacterium 
dentium, q=0.014; Collinsella aerofaciens, q=0.009; 
Bifidobacterium longum, q=0.011) and group 3 (Bacteroides 
vulgatus, q=0.003; Faecalibacterium prausnitzii, q=0.003; 
Eubacterium rectale, q=0.005; Blautia obeum, q=0.014) 
(figure 2A). Similarly, bacterial species enriched in the 
post-FMT faecal microbiota compared with those pre-FMT 
also included members of all BSH groups, including group 
1 (Bacteroides uniformis, q=0.005; Bacteroides ovatus, 
q=0.009; Parabacteroides distasonis, q=0.003), group 2 
(Collinsella aerofaciens, q=0.006; Bifidobacterium dentium, 
q=0.029) and group 3 (Bacteroides vulgatus, q=0.002; 
Eubacterium rectale, q=0.004; Blautia obeum, q=0.009; 
Faecalibacterium prausnitzii, q=0.003) (figure 2B).
Using Piphillin to infer metagenomic content from 
metataxonomic data, there were a significantly reduced 
proportion of sequences predicted to represent both BSH 
(see online supplementary figure 6A) and 7-α-dehydroxylase 
(see online supplementary figure 6B) in pre-FMT samples 
compared with donors, but a significant increase in both 
in post-FMT samples compared with pre-FMT (q<0.01, 
White’s non-parametric test with Benjamini-Hochberg false 
discovery rate (FDR)).
successful FMT for rCDI is associated with restoration of 
normal gut bile acid profiling, including a sustained reduction 
in TCA
We performed faecal bile acid profiling to assess the effect 
of FMT for rCDI on key bile acids known to affect the 
ability of C. difficile to undergo germination or vegetative 
growth.
On multivariate analysis of UPLC-MS bile acid profiling 
data, unsupervised principal component analysis demon-
strated clustering of donor and post-FMT samples, but clear 
separation of both groups from pre-FMT samples (figure 3A). 
Supervised analysis was performed with orthogonal projec-
tions to latent structures discriminant analysis (OPLS-
DA) to analyse the features responsible for discrimination 
between donor and pre-FMT groups (see online supple-
mentary figure 7A), and between pre-FMT and post-FMT 
groups (figure 3B). Discriminatory feature identification 
was performed from OPLS-DA model data via S-plot, with 
pre-FMT samples showing an enrichment in primary bile 
acids (including both conjugated and unconjugated forms) 
and loss of secondary bile acids as compared with post-FMT 
and healthy donor samples (figure 3C, see online supple-
mentary figure 7B). OPLS-DA model validation was 
performed using CV analysis of variance (see online supple-
mentary table 3).
Univariate analysis supported these findings 
(see online supplementary figure 8). Pre-FMT samples 
demonstrated enrichment in TCA and loss of DCA compared 
with healthy donor samples (p<0.01, Mann-Whitney 
U test), while post-FMT samples were characterised by 
restoration of both bile acids back to levels comparable to 
donors (p<0.001, Wilcoxon signed rank-sum test).
Integration of metataxonomic and bile acid profiling data
rCCA modelling was used to integrate metataxonomic and bile 
acid profiling data. The unit representation plot demonstrated 
marked separation of pre-FMT and post-FMT samples, but 
considerable overlap between donor and post-FMT samples 
(figure 4A). A correlation circle plot demonstrated negative 
correlations between levels of TCA and the abundance of 
Figure 2 Species differences in 16S rRNA gene sequencing data in patients with rCDI compared with donor or post-FMT. Extended error bar 
plots, with bacterial species changing significantly measured by White’s non-parametric test with Benjamini-Hochberg correction, using threshold 
of differences between mean proportions >1%. (A) Donor versus pre-FMT; (B) Pre-FMT versus post-FMT. Names in red: known BSH-producing 
bacteria. BSH, bile salt hydrolases; FMT, faecal microbiota transplant; rCDI, recurrent C. difficile infection.
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the bacterial genera Bacteroides and Blautia, both known to 
include representative BSH-producing organisms that were 
significantly increased after FMT in our metaxonomic data 
(figure 4B). In addition, there was positive correlation between 
the genus Clostridium cluster XIVa (known to contain 7-α-de-
hydroxylase producing organisms27 28) and the secondary bile 
acids DCA and lithocholic acid (figure 4B).
Gut bsh gene copy number and bsH enzyme activity is 
restored by successful FMT for rCDI
Having established an association between restoration of 
BSH-producing organisms into the gut microbiota post-FMT 
and recovery of premorbid stool bile acid profiles, we inves-
tigated the effect of FMT for rCDI on BSH expression and 
activity.
Figure 3 Effect of FMT for rCDI on stool bile acid profiles. Assessed via multivariate analysis of UPLC-MS bile acid profiling data. (A) PCA scores 
plot; (B) OPLS-DA scores plot, comparing pre-FMT and post-FMT samples; (C) OPLS-DA S-plot of pre-FMT versus post-FMT data. FMT, faecal 
microbiota transplant; OPLS-DA, orthogonal projections to latent structures discriminant analysis; PCA, principal component analysis; QC, quality 
controls; rCDI, recurrent C. difficile infection; UPLS-MS, ultra performance liquid chromatography mass spectrometry.
Figure 4 Regularised CCA (rCCA) model correlating 16S rRNA gene sequencing data (genus level) and bile acid data. (A) Unit representation plot 
for the two canonical variables (metataxonomics and stool bile acids); (B) Correlation circle plot between pre-FMT and post-FMT samples. Bile acids 
are shown in blue and bacterial genera are shown in orange. FMT, faecal microbiota transplant. 
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bsh gene copy number was significantly reduced in pre-FMT 
samples compared with healthy donors across a range of bsh gene 
groups (p<0.001, Mann-Whitney U test, figure 5A–C). Successful 
FMT was associated with significant enrichment in copy number 
of all bsh gene groups assayed (p<0.05, Wilcoxon signed 
rank-sum test, figure 5A–C) to levels similar to that of healthy 
donors. Similarly, copy numbers of the baiCD operon (encoding 
an enzyme that contributes to 7-α-dehydroxylation29) were 
significantly lower in pre-FMT samples compared with those of 
healthy donors (p<0.01), but were also significantly enriched 
post-FMT (p<0.05, figure 5D). Gene copy number for baiCD 
in donors and post-FMT was noted to be markedly lower than 
for each bsh gene assayed for the same participants. Stool BSH 
enzyme activity showed the same pattern as for bsh gene copy 
number (figure 5E).
To further explore the timescale of gut bile acid/BSH changes 
post-FMT, we analysed serial stool samples collected from 
patients in a randomised trial of colonoscopy versus capsule 
FMT as treatment for rCDI,15 together with donor samples 
and FMT slurry itself. This demonstrated that BSH activity 
was restored (and stool TCA levels greatly reduced) to levels 
comparable to donors within a week of successful FMT, and was 
Figure 5 Effect of FMT on bile-metabolising enzyme gene copy number and BSH enzyme activity. (A) bsh group 1A; (B) bsh group 1B; (C) bsh 
group 3C; (D) baiCD operon of 7-α-dehydroxylase; (E) BSH enzyme activity within faecal supernatant (*, p<0.05; **, p<0.01; ***; p<0.001; 
****, p<0.0001; Mann-Whitney U test for donors versus pre-FMT, Wilcoxon signed rank-sum test for pre-FMT vs post-FMT). BSH, bile salt hydrolases; 
FMT, faecal microbiota transplant. 
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maintained at these levels at 4 weeks and 12 weeks post-FMT 
(p<0.05, Friedman test with Benjamini-Hochberg FDR; 
figure 6A,B). Similarly, BSH activity was significantly reduced 
in pre-FMT samples compared with either donor stool or FMT 
slurry (p<0.01, Mann-Whitney U test; figure 6B).
bsH activity alone is sufficient to fully suppress TCA-mediated 
C. difficile germination in vitro
Our data demonstrated an association between successful FMT, 
breakdown of TCA, and restoration of gut BSH-producing 
microorganisms and BSH functionality. To further explore 
whether these changes were purely associative–or represented 
a true mechanistic pathway–we performed C. difficile batch 
culture germination experiments.
We prepared spent culture supernatants by incubating bacteria 
of interest in broth with 1% w/v TCA. After overnight incuba-
tion, cultures were centrifuged and filter-sterilised. C. difficile 
spores were incubated in sBHI broth supplemented with the 
spent culture supernatant. Using this set-up, C. difficile spores 
incubated with spent culture supernatants without BSH activity 
would have TCA available to stimulate germination and there-
fore grow, while C. difficile spores incubated with spent culture 
supernatants with BSH activity would not have TCA available to 
stimulate germination and would not grow.
Initially, C. difficile spores were incubated with spent superna-
tant from BSH-expressing microorganisms that had been incu-
bated with TCA. The microorganisms selected were those which 
had been shown to be reduced in mean proportion in the gut 
microbiota of pre-FMT patients in comparison to donors and/
or post-FMT samples, and which collectively represented most 
BSH groups. For all C. difficile ribotypes assayed, supernatant 
from the broth of each of the BSH-producing microbes assayed 
significantly reduced C. difficile germination (p<0.0001) 
(figure 7A). As a control, we used spent supernatant from 
TCA-supplemented broth in which vegetative C. difficile had 
been cultured (strain DS1864); this failed to affect C. difficile 
germination.
We assessed whether BSH alone could mediate this inhibition, 
or if it reflected an alternative aspect of bacterial metabolism 
within the cultures. For subsequent batch cultures, strains of 
interest included wild-type E. coli (which lacks a bsh gene), or 
two forms of E. coli into which bsh genes had been cloned (ie, ‘E. 
coli BSHlow’, containing a bsh gene with narrow substrate range 
against conjugated bile acids; and ‘E. coli BSHhigh’, containing 
a bsh gene with high glycine and taurine-deconjugating activity) 
(see online supplementary methods 1.7). While spent superna-
tant from the culture of wild-type/BSH negative E. coli did not 
affect the ability of C. difficile to undergo germination, that from 
both forms of bsh gene-expressing E. coli significantly reduced 
C. difficile germination across all ribotypes tested (p<0.0001, 
Student's t-test) (figure 7B). C. difficile germination was signifi-
cantly lower for all three ribotypes when incubated in TCA-sup-
plemented supernatant from an E. coli BSHhigh batch culture as 
compared with E. coli BSHlow (p<0.05).
C. difficile spores were also cultured in spent supernatant from 
C. scindens which had been incubated with TCA, either by itself 
or also in co-culture with BSH-expressing E. coli. C. scindens 
spent supernatant did not affect C. difficile germination ability 
by itself, but germination was significantly reduced when C. scin-
dens was co-incubated with BSH-expressing E. coli (p<0.01) 
(figure 7C).
Analysis by UPLC-MS confirmed that TCA-supple-
mented batch culture media–which included supernatant 
from wild-type/BSH-negative E. coli, vegetative C. difficile 
and C. scindens culture–had high TCA:CA ratios, consistent 
with little/absent BSH activity within these batch cultures 
Figure 6 Dynamics of changes in taurocholic acid and BSH activity after FMT for rCDI. Assessed via analysis of taurocholate levels in stool ((A) 
as assessed by UPLC-MS) and BSH activity in stool and FMT slurry ((B) assessed via precipitation assay). Samples were collected from patients (and 
their matched donors, along with FMT slurry itself) in a randomised trial of colonoscopy versus capsule FMT as treatment for rCDI15 (*, p<0.05; **, 
p<0.01; ***, p<0.001; Mann-Whitney U test for donors/FMT slurry versus pre-FMT, Friedman test with Benjamini-Hochberg FDR for pre-FMT vs 
post-FMT). BSH, bile salt hydrolases; DCA, deoxycholic acid; FMT, faecal microbiota transplant; rCDI, recurrent C. difficile infection; UPLC-MS, ultra 
performance liquid chromatography mass spectrometry. 
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(see online supplementary figure 9A). Low TCA:CA ratios 
were noted for all other batch cultures, indicating the presence 
of BSH activity. All batch culture experiments in which C. diffi-
cile germination was suppressed were characterised by unde-
tectable levels of DCA within supernatant (other than batch 
cultures containing C. scindens and bsh-expressing E. coli, 
where DCA was detectable). Sterile-filtered spent supernatant 
from batch cultures of BSH-producing microorganisms from 
groups 1, 2 and 3 was found to have BSH activity comparable 
to that found in healthy human stool (see online supplemen-
tary figure 9B).
bsH limits further recurrence of CDI in a mouse model of rCDI
To investigate the hypothesis that BSH-producing bacteria limit 
further recurrence of disease in subjects with rCDI, we adminis-
tered ~109 CFU of either wild-type/BSH-negative E. coli or E. 
coli BSHhigh (n=5 in both groups) into a mouse model of rCDI 
shortly after completion of vancomycin (figure 1A). We used this 
particular protocol to aim to recapitulate the dynamics of FMT 
administration to patients with rCDI. Colonisation of all mice 
with C. difficile was demonstrated at 3 days post-C. difficile spore 
administration (see online supplementary figure 10A), and plate 
counts were used to confirm the titre of E. coli administered 
to mice (see online supplementary figure 10B). E. coli colonisa-
tion of the gut of mice was assessed by plate counts on selective 
media; we identified that on day 12 (ie, 3 days after initial E. 
coli administration), E. coli colonisation was at comparable, high 
levels in both groups of mice (mean CFU per gram of faeces 
of 1.49×109 in mice administered E. coli BSHhigh vs 1.18×10
9 
in mice administered wild-type E. coli, p>0.05, Mann-Whitney 
U test) (figure 1B).
On day 12, C. difficile TVCs were significantly reduced in 
the mice administered E. coli BSHhigh in comparison to those 
administered wild-type/BSH -negative E. coli (figure 1C; mean 
CFU per gram of faeces of 6.92×107 vs 2.70×108, respectively; 
p<0.05, Mann-Whitney U test), equating to a ~70% reduction 
in C. difficile total vegetative cell counts.
DIsCussIOn
In this study, we demonstrate for the first time that a key mech-
anism underlying the efficacy of FMT in treating rCDI is resto-
ration of gut microbiota BSH functionality. Analysis of human 
samples illustrate that this function is restored early after FMT 
and maintained throughout follow-up. In addition, data from 
batch cultures and mouse modelling show that the BSH-medi-
ated hydrolysis of the major C. difficile germinant, TCA, is suffi-
cient to fully suppress C. difficile germination, and limits further 
recurrence of disease within the setting of rCDI. Targeted resto-
ration of gut BSH function is a novel therapeutic approach for 
rCDI that avoids the risks associated with FMT.
The potential role of gut microbiota-host bile acid interactions 
in CDI pathogenesis has been an area of interest since initial 
studies in vitro established that various bile acids differentially 
affected the ability of C. difficile to undergo germination and 
vegetative growth.11 12 30–33 Furthermore, we have also recently 
demonstrated that successful FMT for rCDI is associated with 
stimulation of farnesoid X receptor (FXR) signalling,34 which 
in itself appears to impact the bile acid milieu and consequently 
gut microbiota of the small intestine.35 Subsequent studies have 
demonstrated that the gut of germ-free36 and antibiotic-treated 
mice36–38 –as well as chemostat models of CDI8 or humans with 
rCDI39 40–have enrichment of stool primary bile acids (partic-
ularly conjugated versions) and loss of secondary bile acids, 
with bile acid homeostasis being restored in patients with rCDI 
through FMT.39 Exposure of C. difficile spores to the bile acid 
milieu found in antibiotic-treated mouse caecum37 38 or human 
stool pre-FMT41 was sufficient to cause spore germination, while 
that of the non-antibiotic-treated mouse caecum37 38 or human 
stool post-FMT41 prevented germination and vegetative growth 
of C. difficile.
Rodent studies have demonstrated that 7-α-dehydroxylase-pro-
ducing organisms (in particular, C. scindens) partly protected the 
host against the development of CDI.42 43 However, to date, there 
is not sufficient evidence to demonstrate that 7-α-dehydroxylase 
is responsible for the efficacy of FMT for rCDI. For example, 
Figure 7 C. difficile batch cultures. Changes in spectrophotometer reading (ΔOD600) after overnight incubation of C. difficile spores (three ribotypes 
assayed: 010, 012, 027) in sBHI ±TCA in which bacterial species of interest had been cultured for 24 hours. C. difficile spores in sBHI supplemented 
with 1% TCA (‘No supernatant, 1% TCA’) was used as positive control in all cases; statistical testing shown was performed relative to this sample 
for the particular ribotype under assessment. (A) Batch cultures of BSH-producing microbial species found to be affected by FMT in metataxonomic 
analysis, and vegetative C. difficile. (B) Batch cultures of native E. coli, and two forms of E. coli into which bsh genes had been cloned (E. coli 
BSHlow=E. coli expressing BSH with low deconjugation ability; E. coli BSHhigh=E. coli expressing BSH with high deconjugation activity). (C) Batch 
cultures of C. scindens±BSH expressing E. coli (**, p<0.01; ****, p<0.0001; analysis of variance with multiple group comparisons, Benjamini-
Hochberg correction). Key: 010 is a non-toxigenic C. difficile ribotype, while 012 and 027 are both toxigenic ribotypes. BHI, brain heart infusion; BSH, 
bile salt hydrolases; TCA, taurocholic acid.
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a mouse model of CDI was successfully treated with a mixture 
of six bacteria, none of which are recognised to contain 7-α-de-
hydroxylase activity.44 Furthermore, baiCD gene abundance 
is not different in the stool of patients with CDI and C. diffi-
cile-negative patients (after correction for total bacterial load), 
and the baiCD gene is not consistently detectable in stool after 
successful FMT for rCDI;45 a study using microbial sequencing 
and culture demonstrated comparable results.46 As such, our 
key area of focus in this study was regarding the dynamics of 
BSHs in rCDI and the impact of FMT on BSH functionality. 
Allegretti and coauthors previously demonstrated that predicted 
BSH functionality was significantly reduced in the stool micro-
biota of patients with rCDI compared with healthy controls or 
those with first CDI.14 Our data demonstrate the restoration of 
BSH-producing microorganisms and associated BSH function-
ality post successful FMT for rCDI from the very low levels 
found pre-FMT back to levels similar to that of donors. This 
result is coupled with the loss of primary conjugated bile acids, 
and particularly that of the progerminant TCA.
In patients with and animal models of rCDI, few vegetative 
cells of C. difficile remain in the gut after completion of vanco-
mycin.26 For further recurrence to occur, TCA-mediated germi-
nation of C. difficile is likely to be a key contributory factor. Our 
batch culture and mouse model data demonstrate that hydro-
lysis of TCA by BSH is sufficient to significantly limit C. difficile 
counts in rCDI. To date, no studies have been reported in mice 
that demonstrated restoration of 7-α-dehydroxylase activity 
alone could reduce C. difficile growth. While we have shown 
that degradation of TCA is the major mechanism by which resto-
ration of BSH limits further recurrence in rCDI, an additional 
mechanism may be that BSH creates a larger pool of deconju-
gated primary bile acids, the substrate for further gut bacterial 
enzyme degradation and conversion of primary into secondary 
bile acids within the colon (see online supplementary discussion).
Given the drawbacks that currently exist regarding FMT clin-
ically and the acknowledged need for more refined, targeted 
therapies, we propose that the administration of BSH-producing 
gut microbiota members—or the administration of purified 
BSH enzyme— merits further evaluation as an alternative CDI 
treatment strategy. Administration of a microbial community 
containing BSH-producing bacteria (such as those identified in 
this study) might be expected—like FMT—to require a single 
administration only, given the apparent ability of these organisms 
to easily colonise the gut; in contrast, to attain comparable effi-
cacy, delivery of purified BSH enzyme is likely to require a more 
prolonged administration. Furthermore, while we have demon-
strated proof of concept of ‘BSH therapy’ in a batch culture 
and mouse model setting, this would evidently merit evaluation 
within a clinical trial setting before it could be considered further 
as treatment of human patients with rCDI. It is also important 
to acknowledge that FMT may provide additional mechanisms 
of efficacy in treating rCDI (eg, potentially by competitive niche 
exclusion, related to the near-complete restoration of a diverse 
gut microbial community with high resilience47 48), and such 
benefits may be missed through the use of BSH supplementation 
alone.
As well as a novel treatment for CDI, BSH supplementation 
may be a potential novel strategy for prevention of CDI in those 
at high risk, for example, patients likely to require prolonged 
antibiotic courses. In addition, FMT has a small but appreciable 
failure rate, and there is currently no rational targeted biological 
means by which donors are selected. Assays of stool from poten-
tial donors for BSH-producing organisms and/or BSH function-
ality may be one such means to achieving this aim.
In conclusion, we provide evidence for the first time that 
microbial BSHs are a key mediator of the efficacy of FMT for 
rCDI. This adds to other recent data demonstrating that FMT 
functions by reversing a ‘metabolic dysbiosis’, including through 
the restoration of the short chain fatty acid valerate, which 
potently inhibits the growth of C. difficile without any apparent 
adverse effect on gut commensal bacteria.8 Furthermore, these 
data add further to the growing body of evidence demonstrating 
the central significance of gut microbiota-bile acid interactions 
in colonisation resistance, and demonstrate that targeted restitu-
tion of BSH may be a novel therapy for or preventative strategy 
against CDI that avoids the risks of antimicrobial resistance.
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